Generation Bio Co. (GBIO)

NASDAQ: GBIO · IEX Real-Time Price · USD
2.740
-0.680 (-19.88%)
At close: Jun 14, 2024, 4:00 PM
2.790
+0.050 (1.82%)
After-hours: Jun 14, 2024, 7:58 PM EDT
-19.88%
Market Cap 182.29M
Revenue (ttm) 9.96M
Net Income (ttm) -169.06M
Shares Out 66.53M
EPS (ttm) -2.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 168,566
Open 3.350
Previous Close 3.420
Day's Range 2.720 - 3.420
52-Week Range 0.860 - 6.980
Beta 2.87
Analysts Buy
Price Target 8.00 (+191.97%)
Earnings Date Jul 31, 2024

About GBIO

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating epi... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 2020
Employees 174
Stock Exchange NASDAQ
Ticker Symbol GBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for GBIO stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 191.97% from the latest price.

Price Target
$8.0
(191.97% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

1 day ago - GlobeNewsWire

Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results

- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP)

4 weeks ago - GlobeNewsWire

Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) --   Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today pre...

5 weeks ago - GlobeNewsWire

Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today ann...

7 weeks ago - GlobeNewsWire

Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

2 months ago - GlobeNewsWire

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia

3 months ago - GlobeNewsWire

Generation Bio to Present at the 2024 TD Cowen Health Care Conference

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

3 months ago - GlobeNewsWire

Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

5 months ago - GlobeNewsWire

Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms

CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

7 months ago - GlobeNewsWire

Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

-  Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics

7 months ago - GlobeNewsWire

Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform

CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

8 months ago - GlobeNewsWire

Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: EVLOSPRB
8 months ago - Benzinga

Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA

– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and toler...

8 months ago - GlobeNewsWire

Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit

CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

9 months ago - GlobeNewsWire

Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

11 months ago - GlobeNewsWire

Generation Bio Reports Second Quarter 2023 Financial Results

Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025 Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025

11 months ago - GlobeNewsWire

Generation Bio to Present at the 2023 Jefferies Healthcare Conference

CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

1 year ago - GlobeNewsWire

Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targetin...

1 year ago - GlobeNewsWire

Generation Bio to Present at the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced ...

1 year ago - GlobeNewsWire

Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

1 year ago - GlobeNewsWire

Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

1 year ago - GlobeNewsWire

Generation Bio, Moderna announce collaboration

Shares of Generation Bio Co. GBIO, -0.51% jumped about 28% premarket trading on Thursday after the company announced a collaboration with Moderna Inc. MRNA, -2.58% to to develop novel nucleic acid the...

Other symbols: MRNA
1 year ago - Market Watch

Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines

Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nano...

Other symbols: MRNA
1 year ago - Accesswire

Generation Bio to Participate in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce...

1 year ago - GlobeNewsWire

Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced...

1 year ago - GlobeNewsWire